Table 2.

Trials of other targeted therapies in patients with metastatic differentiated thyroid cancer.

Agent	Celecoxib [17]	Vorinostat [18]	Thalidomide [19]	Lenalidomide [20]	Rosiglitazone [21]	Bexarotene [22]	Selumetinib [23]
Mechanism	COX-2 inhibitor	Histone deacetylase inhibitor	Antiangiogenesis	Antiangiogenesis	RAIU restoration	RAIU restoration	RAIU restoration
N enrolled	32	19	36	25	25	11	12
Histology (DTC), n	32	16	28	25	25	11	12
Outcome	RECIST	RECIST	Tumor volume	Tumor volume	Tumor volume	Tumor volume	Tumor volume
CR%	0	0	0	0	0	0	0
PR%	3	0	18	22	20	0	42
SD%	3	56	32	44	12	18	17

RAIU: radioactive iodine uptake; COX-2: cyclooxygenase-2; DTC: differentiated thyroid cancer; RECIST: response evaluation criteria in solid Tumors; CR: complete response; PR: partial response; SD: stable disease.